赵志强
赵志强
职称:副主任医师
科室:骨肿瘤科
学位/学历:博士
导师资格:硕士生导师
简介:

秉承骨与软组织肿瘤领域的先进理念以及规范化诊治和精细化手术原则,致力于:

1. 脊柱和四肢骨转移癌的微创手术及综合治疗;

2. 脊柱和骶骨肿瘤的切除与重建;

3. 四肢和骨盆恶性骨肿瘤保肢治疗(儿童骨肿瘤精细化保肢);

4. 软组织肉瘤的手术及综合治疗。

出诊时间
专家门诊
周一
Mon
周二
Tue
周三
Wed
周四
Thur
周五
Fri
周六
Sat
周日
Sun
上午
AM
下午
PM
出诊时间以实际为准

医疗特长:

秉承骨与软组织肿瘤领域的先进理念以及规范化诊治和精细化手术原则,致力于:

1. 脊柱和四肢骨转移癌的微创手术及综合治疗;

2. 脊柱和骶骨肿瘤的切除与重建;

3. 四肢和骨盆恶性骨肿瘤保肢治疗(儿童骨肿瘤精细化保肢);

4. 软组织肉瘤的手术及综合治疗。

 

研究方向:

主持国家自然科学基金(青年基金、面上项目)2项;

临床研究:恶性骨肿瘤保肢及脊柱转移癌的微创治疗;

基础研究:骨肉瘤及软组织肉瘤的发病和转移机制研究。

主要教育和工作经历:

1.  2021/12-至今      中山大学附属第一医院,副主任医师

2.    2018/12-2021-12, 中山大学附属第一医院,主治医师

3.    2015/07-2018/12, 中山大学附属第一医院,住院医师

4.    2014/05-2015/04, Cedars-Sinai Medical Center, University of California, School of Medicine, LA, USA. (联培博士)

5.    2013/10-2014/05, Huntsman Cancer Institute, University of Utah, USA. (联培博士)

6.  2012/09-2015/06, 中山大学,附属第一医院,博士

7.  2009/09-2012/06, 中山大学,附属第一医院,硕士

8.  2004/09-2009/06, 武汉大学,临床医学系,学士

 

社会兼职:

论著:

(1)    Hongyi Li#, Jian Tu#, Zhiqiang Zhao#, Lijuan Chen, Yueting Qu, Hongbo Li, Hao Yao, Xiaoshuai Wang, Dung-Fang Lee, Jingnan Shen, Lili Wen, Gang Huang#, Xianbiao Xie#. Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas. Theranostics. 2020; 10(21): 9477–9494.

(2)    Zhiqiang Zhao#, Qinglin Jin#, Xianbiao Xie, Yongqian Wang, Tiao Lin, Junqiang Yin, Gang Huang, Changye Zou*,Jingnan Shen*. Plastic lengthening amputation with vascularized bone grafts in children with bone sarcoma: a preliminary report. World Journal of Surgical Oncology. volume 18, Article number: 246 (2020)(IF:2.754)2020 Sep 15;18(1):246.

(3)    Zhiqiang Zhao#, Mansi Wu#, Xuelin Zhang#, Qinglin Jin, Yongqian Wang, Changye Zou, Gang Huang, Junqiang Yin, Xianbiao Xie*, Jingnan Shen*. CB-5083, an inhibitor of P97, suppresses osteosarcoma growth and stem cell properties by altering protein homeostasis. Am J Transl Res 2020;12(6):2956-2967

(4)    Jiajun Zhang#, Weihai Liu#, Changye Zou#, Zhiqiang Zhao#, Yuanying Lai, Zhi Shi, Xianbiao Xie, Gang Huang, Yongqian Wang, Xuelin Zhang, Zepei Fan, Qiao Su, Junqiang Yin*, Jingnan Shen*,Targeting super-enhancer-associated oncogenes in osteosarcoma with THZ2, a covalent CDK7 inhibitor. Clin Cancer Res. 2020 Jun 1;26(11):2681-2692.

(5)    Changye Zou#, Zhiqiang Zhao #, Tiao Lin , Yongfu Huang , Xianbiao Xie , Junqiang Yin , Gang Huang , Bo Wang*,Jingnan Shen*. Long-term outcomes of limb salvage treatment with custom-made extendible endoprosthesis for bone sarcoma around the knee in children. J Orthop Surg Res. 2020 Jan 16;15(1):14. doi: 10.1186/s13018-019-1534-x.

(6)    Demeng Chen#,Zhiqiang Zhao#, Zixin Huang, Du-Chu Chen, Xin-Xin Zhu, Yi-Ze Wang, Ya-Wei Yan, Shaojun Tang, Subha Madhavan, Weiyi Ni, Zhan-peng Huang, Wen Li, Weidong Ji, Huangxuan Shen, Shuibin Lin*, Yi-zhou Jiang*, Super enhancer inhibitors suppress MYC driven transcriptional amplification and tumor progression in osteosarcoma. Bone Research (2018) 6:11  

(7)    Zhao Z#, Jia Q#, Wu MS#, Xie X, Wang Y, Song G, Zou CY, Tang Q, Lu J, Huang G, Wang J, Lin DC, Koeffler HP, Yin JQ*, Shen J*. Degalactotigonin, a natural compound from Solanum nigrum L., inhibits growth and metastasis of osteosarcoma through GSK3β inactivation-mediated repression of the Hedgehog/Gli1 pathway. Clin Cancer Res. 2018 Jan 1;24(1):130-144.  

(8)    Weihai Liu#, Zhiqiang Zhao#, Yongqian Wang#, Wuguo Li, Qiao Su, Qiang Jia, Jiajun Zhang, Xuelin Zhang, Jingnan Shen * and Junqiang Yin *. Dioscin inhibits stem-cell-like properties and tumor growth of osteosarcoma through Akt/GSK3/β-catenin signaling pathway. Cell Death & Disease, 2018. 9(3): p. 343.  

 

专著:

 

其他主要工作成绩(比如获奖情况):